Humacyte assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Humacyte (HUMA) with a Buy rating and $4 price target Humacyte’s lead product, Symvess, was approved as a vascular conduit in extremity vascular trauma at the end of 2024 and management initiated U.S. commercialization of the product in February, notes the analyst, who is “encouraged” that the product achieved approximately $0.5M in the first two months of launch. The company has completed enrollment in the Phase 3 V007 study evaluating the acellular tissue engineered vessel for arteriovenous access for hemodialysis and in order to “monetize Symvess to the fullest extent,” the company is conducting two additional Phase 2 studies, V002 and V004, evaluating the ATEV in peripheral artery disease, the analyst added.